For patients with advanced cervical cancer, cisplatin plus pemetrexed may be effective
the ONA take:
According to a new study published in the Journal of Clinical Oncology, cisplatin plus pemetrexed improved response rates and survival rates of patients with advanced cervical cancer. In the phase 2 study, researchers assigned patients with advanced, persistent, or recurrent cervical cancer to received either cisplatin in combination with pemetrexed or paclitaxel.
Researchers found that patients with no prior history of chemotherapy that received cisplatin plus pemetrexed had a 31% response rate for a duration of up to 7 months and an overall survival of 12 months. Patients that received cisplatin plus paclitaxel had a 29% response rate for a duration of up to 6 months and an overall survival of 13 months.
Furthermore, the pemetrexed combination was observed to be less toxic compared with the paclitaxel combination. Researchers also observed increased survival rates when adding bevacizumab to the paclitaxel combination, so researchers suggest possibly adding bevacizumab to the pemetrexed combination.
According to the Centers for Disease Control and Prevention (CDC), cervical cancer used to be the leading cause of cancer-related death in women in the United States, but regular Pap screenings have led to early cancer detection and decreased mortality.
Cisplatin plus pemetrexed improved response rates in patients with advanced cervical cancer.
Combining a standard chemotherapy drug with a second drug that stops cells from dividing improves both the survival and response rates for those with advanced cervical cancer, a new study by UT Southwestern Medical Center cancer researchers finds.
The cancer-fighting cocktail, which combines the chemotherapy drug cisplatin with pemetrexed - an agent that stops cancer cells from dividing - showed promising results for advanced, persistent, or recurrent cervical cancer.
- Novel Blood Test Detects Cancer, Locates Tumor Without Invasive Procedures
- Cabozantinib Activates Innate Immune Response, Eliminating Prostate Cancer
- Shorter Treatment of Breast Cancer with Trastuzumab May Lead to Improved Results
- Colorectal Cancer Rates Increased Sharply Among Generation X and Millennials
- Pneumonia Associated With Common Cold May Cause Fatal Illness in Stem Cell Transplant Recipients
- Early Palliative Care Reduced ICU Use in Patients With Advanced Cancer
- Ginger Extract Raises Antioxidant Levels in Patients Undergoing Chemotherapy
- Nurse Navigators Improve Physician Engagement in Pretreatment Discussions
- Screening Increases Early Palliative Care, Reduces Aggressive EOL Measures
- Antiperspirants/Deodorants and Breast Cancer (Fact Sheet)
- Genome Sequencing Explains Resistance to CTLA-4 and PD-1 Inhibitors in Metastatic Melanoma
- Lifestyle Choices Have Greater Influence on Colon and Rectal Cancer Risk
- Kidney Cancer Metastases in Lung May Hide Undiagnosed Primary Lung Cancer
- Nasal Biomarker in Smokers Could Predict Lung Cancer
- Arm Lymphoscintigraphy After Axillary Lymph Node Dissection or Sentinel Lymph Node Biopsy in Breast Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|